Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis

[1] Rastmanesh R(2014)Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms Clin Genitourin Cancer 12 143-148

[2] Hejazi J(2014)Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders Cancer Prev Res 7 867-885

[3] Marotta F(2013)Metformin and cancer in type 2 diabetes Diabetes Metab J 37 113-116

[4] Hara N(2014)Testosterone and glucose metabolism in men: current concepts and controversies J Endocrinol 220 R37-R55

[5] Gandini S(2013)Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies Prostate Cancer Prostatic Dis 16 151-158

[6] Park HK(2012)Glucose-lowering agents and the patterns of risk for cancer: a study with the general practice research database and secondary care data Diabetologia 55 654-665

[7] Grossmann M(2009)Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2125-2135

[8] Bansal D(2010)Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (a diabetes outcome progression trial) and RECORD (Rosiglitazone evaluated for cardiovascular outcomes and regulation of Glycaemia in diabetes) clinical trials Diabetologia 53 1838-1845

[9] Bhansali A(2006)Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427-2443

[10] Kapil G(2012)Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients Diabetes Care 35 1002-1007

[1] Rastmanesh R(2014)Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms Clin Genitourin Cancer 12 143-148

[2] Hejazi J(2014)Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders Cancer Prev Res 7 867-885

[3] Marotta F(2013)Metformin and cancer in type 2 diabetes Diabetes Metab J 37 113-116

[4] Hara N(2014)Testosterone and glucose metabolism in men: current concepts and controversies J Endocrinol 220 R37-R55

[5] Gandini S(2013)Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies Prostate Cancer Prostatic Dis 16 151-158

[6] Park HK(2012)Glucose-lowering agents and the patterns of risk for cancer: a study with the general practice research database and secondary care data Diabetologia 55 654-665

[7] Grossmann M(2009)Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2125-2135

[8] Bansal D(2010)Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (a diabetes outcome progression trial) and RECORD (Rosiglitazone evaluated for cardiovascular outcomes and regulation of Glycaemia in diabetes) clinical trials Diabetologia 53 1838-1845

[9] Bhansali A(2006)Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427-2443

[10] Kapil G(2012)Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients Diabetes Care 35 1002-1007